Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Pancreatic Neoplasms 2Skin Neoplasms 1Multiple Myeloma 1Motor Activity 1Melanoma 1Leukemia, Myeloid, Acute 1EBV-associated Tumors 1Colorectal Cancer Metastatic 1Carcinoma, Merkel Cell 1Advanced Solid Tumor 1

Interventions

Cyclophosphamide 6Dexamethasone 5fludarabine 4Bortezomib 468Ga-pentixafor 4Melphalan 3Lenalidomide 3Granulocyte Colony-Stimulating Factor 3Positron Emission Tomography Computed Tomography 2Fluorodeoxyglucose F18 2Filgrastim 2tocilizumab 1ruxolitinib 1pomalidomide 1methyl prednisolonate 1ioversol 1iberdomide 1fludarabine phosphate 1eltrombopag 1elotuzumab 1daratumumab 1carfilzomib 1blinatumomab 1Thalidomide 1Tacrolimus 1Simvastatin 1Prochlorperazine 1Pemetrexed 1Ondansetron 1Mycophenolic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Multiple Myeloma × Immune Checkpoint Inhibitors × Clear all
NCT03943472 2021-08-31

BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma

Hrain Biotechnology Co., Ltd.

Phase EARLY_PHASE1 Unknown
10 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡